CDMO

The ₹192.5 crore transaction marks Granules India's entry into the CDMO segment and expands its presence in peptide-based APIs

New organisational structure consolidates virus filtration, testing services, and CDMO operations to enhance service delivery for…

US pharma manufacturing sees investment surge amid tariff shifts, while BRICS nations push regulatory reforms to expand biosimilar…

As the sector adapts to technological advancements, regulatory requirements, and increasing competition, several leadership role…

Tarunesh Madan highlights the evolving leadership landscape in Indian pharma, exploring emerging roles, global expansion…

Acquisition strengthens Granules’ entry into the peptide-based therapeutics market and enhances CDMO capabilities through Senn’s…

Acquisition strengthens capabilities in biologics, ADCs, and integrated drug discovery

Bill Coyle, principal, ZS, discusses India's growing role in biologics from a CDMO perspective and how AI is shaping pharma.…

India’s pharma exports are projected to grow from $27 billion in 2023 to $350 billion by 2047, positioning the nation as a global…

Veeda Lifesciences represents the brand that integrates Veeda Clinical Research, Health Data Specialists, and Bioneeds India